Mineralys Therapeutics, Inc. (MLYS): 7 insider purchases in the last two years.
| Filed | Insider | Shares | Price | Value | Type |
|---|---|---|---|---|---|
| Mar 31, 2026 | Shah Rajeev M. Director | 369,000 | $23.75 | $8.8M | no history |
| Sep 8, 2025 | Ra Capital Management, L.P. Director | 1,176,470 | $25.50 | $30.0M | no history |
| Sep 8, 2025 | Akkaraju Srinivas Director | 588,235 | $25.50 | $15.0M | no history |
| Apr 25, 2025 | Slingsby Brian Taylor Director, TenPercentOwner | 259,259 | $13.50 | $3.5M | no history |
| Mar 17, 2025 | RA Capital Nexus Fund III, L.P. Director | 1,296,296 | $13.50 | $17.5M | no history |
| Mar 17, 2025 | Akkaraju Srinivas Director | 600,000 | $13.50 | $8.1M | no history |
| Mar 17, 2025 | Samsara BioCapital, L.P. TenPercentOwner | 600,000 | $13.50 | $8.1M | no history |
Open-market purchases from SEC Form 4. "Opportunistic" = this insider trades every year but not on a fixed schedule (Cohen, Malloy & Pomorski); "routine" buys carry little information.
Free account. Know when insiders, famous funds or Congress trade it.